# Piramal Pharma Limited, Sangareddy District, India – FDA Inspections

Source: https://www.keypedia.com/companies/piramal-pharma-limited/426a2612-5a5c-4bc9-9073-420430b16072

> Inspection records and compliance data for Piramal Pharma Limited in Sangareddy District. 6 FDA inspections on record, 1 Form 483, last inspected February 13, 2026.

---

## Details

- Name: Piramal Pharma Limited
- FEI Number: 3003803288
- Business Operations: API MANUFACTURE, API/FDF ANALYTICAL TESTING, FDF MANUFACTURE, PACK
- Address Line 1: Sy No. 7-70, 70/1 & 70/2, Digwal Village, Kohir Mandal
- City: Sangareddy District
- Country Name: India
- Address: Sy No. 7-70, 70/1 & 70/2, Digwal Village, Kohir Mandal, Sangareddy District, India
- Country: India

## Related Documents

- [FDA Inspection 1308840 - Piramal Pharma Limited - 2026-02-13](https://www.keypedia.com/records/fda_inspections/piramal-pharma-limited/9d76a7c9-b428-4f2e-a69d-3ef804424f97) — source: FDA, date: February 13, 2026
- FDA Inspection 1308840 - Piramal Pharma Limited - 2026-02-13 — source: FDA, date: February 13, 2026
- [483 - Piramal Pharma Limited - 2025-02-13](https://www.keypedia.com/records/483/piramal-pharma-limited/ac3d292a-1498-4b43-8212-a948c2837186) — source: FDA, date: February 13, 2025
- FDA Inspection 1204395 - Piramal Pharma Limited - 2023-03-31 — classification: No Action Indicated (NAI), source: FDA, date: March 31, 2023
- FDA Inspection 1049434 - Piramal Pharma Limited - 2018-03-30 — classification: No Action Indicated (NAI), source: FDA, date: March 30, 2018
- FDA Inspection 1049434 - Piramal Pharma Limited - 2018-03-30 — classification: No Action Indicated (NAI), source: FDA, date: March 30, 2018
- FDA Inspection 967695 - Piramal Pharma Limited - 2016-03-25 — classification: No Action Indicated (NAI), source: FDA, date: March 25, 2016
- FDA Inspection 863820 - Piramal Pharma Limited - 2014-01-20 — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 20, 2014
- FDA Inspection 767041 - Piramal Pharma Limited - 2012-02-02 — classification: No Action Indicated (NAI), source: FDA, date: February 2, 2012

## Related Companies

- [Hamari PFST, Ltd.](https://www.keypedia.com/companies/hamari-pfst-ltd/17548bf6-b8d5-4469-be75-78ca6f0f7bd5)
- [Changzhou Pharmaceutical Factory](https://www.keypedia.com/companies/changzhou-pharmaceutical-factory/eea165e1-3df2-47c8-94b9-e8400af46bc4)
- [Boehringer Ingelheim Pharma GmbH & Co. KG](https://www.keypedia.com/companies/boehringer-ingelheim-pharma-gmbh-co-kg/bcb705bf-98ed-451f-a79d-b6223d2ed263)
- [Glaxo Operations UK Limited](https://www.keypedia.com/companies/glaxo-operations-uk-limited/203ed5e0-7ae4-490f-b37a-9293e17eae84)
- [Cohance Lifesciences Limited](https://www.keypedia.com/companies/cohance-lifesciences-limited/c01306bf-33dc-4f28-a424-11cda764a0d5)
- [Xellia Pharmaceuticals ApS](https://www.keypedia.com/companies/xellia-pharmaceuticals-aps/5d9704ca-114e-4a65-abca-966a5c4e2a57)
- [Sumitomo Dainippon Pharma Co., Ltd.](https://www.keypedia.com/companies/sumitomo-dainippon-pharma-co-ltd/40ead027-5fd5-4deb-a37b-40301cffd612)
- [Excella GmbH & Co. KG](https://www.keypedia.com/companies/excella-gmbh-co-kg/82bb94ef-8b2e-4e51-8c40-b71a184257f1)
- [Cipla Limited](https://www.keypedia.com/companies/cipla-limited/ca77117b-0afe-4b51-bdc2-82ee1e242ec8)
- [Bayer AG](https://www.keypedia.com/companies/bayer-ag/c999165f-4c13-4f49-b979-087064975cb0)

## Related Officers

- [Investigator](https://www.keypedia.com/people/patty-p-kaewussdangkul/1f0961fc-216e-4580-830a-56a76c0e7cea)
